US45674E1091 - Common Stock
IN8BIO INC
NASDAQ:INAB (9/26/2023, 3:30:02 PM)
1.15
-0.04 (-3.36%)
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 26 full-time employees. The company went IPO on 2020-11-12. The company is focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead product candidates are in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation. The company is also focused on patient enrollment in the Company-sponsored Phase 2 clinical trial of INB-400 in which autologous genetically modified gamma-delta T cells will be assessed in newly diagnosed GBM patients. Its DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing GBM and other solid tumor types.
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK
P: 16466006438.0
CEO: William Ho
Employees: 26
Website: https://www.in8bio.com
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and...
IN8bio (INAB) disclosed in an SEC filing dated Sept 15 that director Graff Jeremy R
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...
Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated...
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative...
Here you can normally see the latest stock twits on INAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: